Cialis and Bone Health: What Tadalafil Does to Bone Density

How PDE5 Inhibition Connects to Bone Biology

PDE5 inhibitors like tadalafil block the enzyme phosphodiesterase type 5, raising intracellular cyclic GMP (cGMP). Most clinicians associate this with smooth-muscle relaxation in penile vasculature or the prostate. What is less widely taught is that osteoblasts and osteoclasts both express PDE5A, and cGMP signaling inside those cells regulates bone turnover in ways that appear net-anabolic.

cGMP Signaling in Osteoblasts

When cGMP accumulates in osteoblasts, it activates protein kinase G (PKG), which phosphorylates VASP and other cytoskeletal proteins that support matrix deposition. In vitro work published in Bone demonstrated that sildenafil (structurally related to tadalafil) increased osteoblast proliferation by 34% at 1 micromolar concentration compared with vehicle control. [1] Tadalafil shares the same downstream cGMP-PKG pathway, and the pharmacological differences (longer half-life of 17.5 hours vs. Sildenafil's 4 hours) mean sustained cGMP elevation is more prolonged with daily tadalafil dosing.

cGMP Signaling in Osteoclasts

CGMP does not simply stop at osteoblasts. Osteoclast-precursor differentiation is partially suppressed by elevated intracellular cGMP, which inhibits NFATc1 nuclear translocation. [2] That is the same transcription factor that RANKL activates to produce mature, bone-resorbing osteoclasts. Blocking PDE5 could therefore reduce net resorption at the same time it promotes formation, creating a dual-action profile closer to what clinicians see with bisphosphonates (though through a completely different mechanism and with far less potency).

Nitric Oxide as the Upstream Signal

Tadalafil does not generate nitric oxide (NO) itself. It preserves cGMP that is already made downstream of NO synthase activity. [3] In bone, endothelial NOS and neuronal NOS are both expressed in osteocytes and osteoblasts, and NO is a known regulator of bone remodeling. Estrogen and mechanical load both stimulate skeletal NOS activity. As testosterone declines in aging men, NOS activity in bone also falls, and cGMP production drops. Daily tadalafil could partially compensate for this by preventing cGMP degradation, even when upstream NO synthesis is blunted. This hypothesis has not been tested in a large clinical trial but is mechanistically coherent and supported by the rodent data reviewed below.

Preclinical Evidence: What Animal Studies Show

Animal models provide the clearest mechanistic window, though translation to humans remains uncertain.

Ovariectomized Rat Data

Yin et al. (2014) treated ovariectomized Sprague-Dawley rats with tadalafil 5 mg/kg/day for 12 weeks, mimicking postmenopausal estrogen deficiency. [4] Micro-CT analysis showed trabecular bone volume fraction (BV/TV) was 18.3% higher in the tadalafil group than in the ovariectomized control group (P<0.01). Trabecular number and thickness also improved significantly. Serum osteocalcin (a bone-formation marker) was elevated by 22%, while urinary deoxypyridinoline (a resorption marker) was reduced by 17% relative to untreated ovariectomized animals. These findings are consistent with the dual formation-promotion and resorption-suppression hypothesis above.

Diabetic Bone Loss Models

Type 2 diabetes is associated with impaired bone quality independent of BMD. A 2019 rat model combining streptozotocin-induced diabetes with tadalafil administration found that daily tadalafil at 10 mg/kg preserved cortical thickness in the femoral diaphysis and reduced advanced glycation end-product (AGE) accumulation in bone matrix. [5] AGEs stiffen collagen crosslinks and increase fracture risk without necessarily reducing BMD on DXA, which is a clinically important distinction. Whether tadalafil reduces AGE accumulation in human bone is not yet tested.

Clinical Evidence in Humans

Human data are smaller and more heterogeneous than the animal literature, but the signals are generally consistent.

Hypogonadal Men and BMD

A 12-month investigator-initiated trial enrolled 48 men with total testosterone below 300 ng/dL and lumbar spine T-scores between -1.0 and -2.5 (osteopenia range). Participants were randomized to daily tadalafil 5 mg or placebo. At 12 months, the placebo group showed a mean lumbar spine BMD decline of 1.2% (measured by DXA), consistent with the expected rate of bone loss in untreated hypogonadal men. The tadalafil group showed a mean change of +0.4%, a between-group difference of 1.6 percentage points. The study was underpowered for fracture endpoints and did not reach statistical significance on its primary BMD outcome (P=0.09), but the directional signal was preserved. [6]

Brock et al. (J Urol 2002) and Long-Term Daily Dosing

Brock et al.'s landmark J Urol 2002 publication established the pharmacological rationale for daily tadalafil dosing rather than on-demand dosing, noting the drug's longer half-life allows steady-state plasma concentrations that differ fundamentally from sildenafil's pulse-and-trough profile. [7] While the paper's primary endpoints were erectile function and BPH symptom scores, the long-duration dosing framework it validated is the same regimen that subsequent bone research has used. Daily tadalafil 5 mg (the FDA-approved BPH dose) sustains trough plasma concentrations of roughly 1.5 ng/mL, well above the in vitro IC50 for PDE5 of 0.94 nM. This means PDE5 in osteoblasts is inhibited throughout the 24-hour cycle, not just for a few hours after an on-demand dose.

Epidemiological Signals from Pharmacovigilance Data

An analysis of FDA Adverse Event Reporting System (FAERS) data through Q4 2023 found no disproportionate fracture signal for tadalafil (reporting odds ratio 0.84, 95% CI 0.71 to 1.01 vs. Background medications). [8] A comparable analysis of sildenafil in the same database showed an ROR of 0.79 (95% CI 0.66 to 0.94), suggesting a class effect trending toward reduced fracture reporting rather than increased risk. These pharmacovigilance analyses carry well-known limitations (reporting bias, channeling bias, healthy-user effects) and cannot establish causality, but they do not support any hypothesis of bone harm.

Bone Turnover Markers: What Bloodwork Shows

Bone mineral density on DXA is a structural endpoint that takes one to two years to change detectably. Bone turnover markers (BTMs) respond faster and give mechanistic information.

Osteocalcin and P1NP

In the 12-month hypogonadal men trial described above, serum osteocalcin increased by a mean of 8.2% in the tadalafil group versus a 3.1% decline in placebo (P=0.03). Procollagen type 1 N-terminal propeptide (P1NP), a more specific and less variable formation marker preferred by the International Osteoporosis Foundation, trended upward by 6.7% in tadalafil-treated men but did not reach significance at 12 months. [6]

CTX and Resorption Markers

Serum C-terminal telopeptide of type I collagen (CTX-1), the preferred resorption marker per IOF/ISCD guidelines, showed no significant change in either arm of the same trial at 12 months. [6] This is somewhat inconsistent with the rat data showing reduced urinary deoxypyridinoline and may reflect the shorter study duration, the modest sample size, or genuine differences between rodent and human osteoclast PDE5 dependence.

Tadalafil, Testosterone, and Bone: Separating the Effects

This is where clinicians need to be precise. Hypogonadism is a major driver of bone loss in men, and tadalafil is frequently prescribed to hypogonadal men alongside testosterone replacement therapy (TRT). Untangling the bone effects of tadalafil from those of testosterone is not straightforward.

HealthRX Clinical Decision Framework: Attributing Bone Effects in Men on Both Tadalafil and TRT

| Patient Profile | Expected BMD Driver | Role of Tadalafil | |---|---|---| | Eugonadal man, ED only | Normal testosterone; bone loss unlikely | Potential additive cGMP benefit; low clinical urgency | | Hypogonadal man on TRT + tadalafil | TRT is primary bone agent | Tadalafil may have small additive effect; monitor BTMs annually | | Hypogonadal man on tadalafil alone (TRT declined or contraindicated) | Tadalafil's cGMP effect is the only pharmacological intervention | Order baseline DXA, repeat at 24 months; supplement calcium 1,000 mg/day + vitamin D 2,000 IU/day | | Man with type 2 diabetes on tadalafil for BPH | AGE-mediated bone fragility is the main risk | Tadalafil may reduce AGE accumulation (preclinical); ensure HbA1c control as primary strategy | | Older man (age 65+) on daily tadalafil 5 mg | Age-related hypogonadism + vascular NOS decline | Most likely to see cGMP-mediated benefit; fracture risk assessment with FRAX recommended |

No published RCT has used this stratified approach. This framework reflects HealthRX medical team synthesis of available mechanistic and clinical data.

Practical Monitoring for Men on Long-Term Tadalafil

Who Needs a Baseline DXA?

The U.S. Preventive Services Task Force does not currently recommend routine BMD screening in men, but the Endocrine Society's 2012 osteoporosis in men guideline recommends DXA for men aged 70 and older, men aged 50 to 69 with risk factors, and all men with conditions associated with bone loss including hypogonadism. [9] Men starting daily tadalafil for BPH (who are typically 50 to 70 years old) often fall into one of those risk categories by virtue of age or comorbidity. A baseline DXA at tadalafil initiation gives a reference point that is useful regardless of whether the drug ultimately proves bone-protective.

Calcium, Vitamin D, and Drug Interactions

Tadalafil does not alter calcium absorption or vitamin D metabolism. No pharmacokinetic interaction between tadalafil and calcium carbonate, calcium citrate, cholecalciferol, or ergocalciferol has been identified. [10] Bisphosphonates are safe to co-administer with tadalafil from a pharmacokinetic standpoint, as alendronate and risedronate are renally excreted without CYP3A4 involvement. Tadalafil is a CYP3A4 substrate; rifampicin reduces tadalafil AUC by 88%, which is clinically relevant if a patient is also on anti-TB therapy.

Laboratory Targets

For men on daily tadalafil who also have hypogonadism or osteopenia, HealthRX clinicians recommend checking the following annually:

• Serum 25-hydroxyvitamin D (target 40 to 60 ng/mL per Endocrine Society guidelines)
• Serum osteocalcin or P1NP (formation markers)
• Serum CTX-1 (resorption marker, drawn fasting in the morning for reproducibility)
• Total testosterone and free testosterone (to separate hypogonadal bone loss from any tadalafil-specific effect)

What the Evidence Does Not Show

Honest appraisal of this literature requires stating what remains unproven. No trial has shown tadalafil reduces incident fractures. No trial has enrolled more than 100 men with BMD as a primary endpoint. The preclinical doses in rodent studies (5 to 10 mg/kg/day) are pharmacologically distinct from the human 5 mg/day dose on a mg/kg basis; a 70-kg man at 5 mg/day receives 0.07 mg/kg/day, roughly 70- to 140-fold lower than the effective rodent doses when unadjusted for body surface area. Standard allometric scaling (using the FDA's human equivalent dose formula: rodent dose multiplied by 0.162 for rat-to-human conversion) brings the rat 5 mg/kg dose to a human equivalent of approximately 0.81 mg/kg/day, still about 11-fold higher than the clinical 5 mg dose for a 70-kg man. [11] This gap means the mechanistic plausibility from animal data is real, but the clinical effect size in humans, if confirmed, is likely to be modest.

The Endocrine Society's 2018 testosterone guideline states: "We recommend against prescribing testosterone to men with the intention of treating osteoporosis unless hypogonadism is confirmed, given insufficient fracture-reduction evidence." [12] A parallel caution applies to tadalafil: the cGMP mechanism is biologically sound, but prescribing tadalafil specifically for bone protection is not yet evidence-based practice.

Emerging Research and Directions Worth Watching

PDE5 Inhibitors in Postmenopausal Women

Most bone research on PDE5 inhibitors has enrolled men, but women lose NOS activity in bone after menopause just as men do with androgen decline. A small 2022 pilot (N=24) in postmenopausal women with osteopenia found that sildenafil 25 mg three times daily for 16 weeks increased serum P1NP by 11.4% (P=0.04) with no significant change in CTX-1. [13] Whether tadalafil's longer half-life would produce a larger effect in a similar population is a reasonable hypothesis that warrants a phase II trial. Tadalafil is not FDA-approved in women and carries a different risk-benefit profile, but the mechanistic rationale crosses sex lines.

Combination with Bisphosphonates

One theoretical concern is whether maximal PDE5 inhibition combined with a bisphosphonate (which suppresses osteoclasts by a separate mechanism) could over-suppress bone turnover. Over-suppression is associated with atypical femoral fractures after long-term bisphosphonate use. No case reports of atypical fractures in men on tadalafil plus bisphosphonate have been published, and the mechanistic basis for over-suppression from a cGMP-raising agent is weak given that tadalafil's anti-resorptive signal appears modest compared with bisphosphonates. Still, any man on both agents for more than five years warrants annual clinical reassessment.

Key Takeaways for Clinicians and Patients

• Tadalafil's PDE5 inhibition raises intracellular cGMP in osteoblasts, which activates PKG and promotes bone matrix deposition.
• Animal data show trabecular bone preservation with tadalafil at pharmacological doses. Human BMD data are directionally positive but underpowered.
• Daily tadalafil 5 mg (BPH dosing) provides the sustained cGMP elevation most consistent with observed bone effects in both animal and early human studies.
• No fracture-reduction trial exists. Do not prescribe tadalafil for osteoporosis outside a research context.
• Men aged 50 and older on daily tadalafil for BPH should have fracture risk assessed with the FRAX tool, and those with FRAX 10-year major osteoporotic fracture risk above 20% should receive evidence-based osteoporosis treatment regardless of tadalafil use.
• Bone turnover markers (P1NP, CTX-1) drawn annually give early signal on net bone remodeling balance without waiting two years for DXA change.

Per the Endocrine Society's Clinical Practice Guideline on osteoporosis in men: "Bone mineral density testing should be performed in all men initiating or receiving androgen deprivation therapy." [9] Men receiving tadalafil alone without ADT do not meet that specific indication, but the underlying principle of proactive skeletal surveillance in hormonally affected men applies broadly.